Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided immunosuppression taper after allogeneic stem cell transplantation in AML
2013-000238-37Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of cyclosporine and mycophenolate mofetil in acute myeloid leukemia (AML) and Minimal residual disease of acute myeloid leukemia after allogeneic stem cell transplantation, sponsored by Amsterdam University Medical Center. Primary endpoint: Cumulative incidence of hematological relapse. Started Apr 2013; status: terminated.
02
Drugs
cyclosporinemycophenolate mofetil
03
Conditions
acute myeloid leukemia (AML)Minimal residual disease of acute myeloid leukemia after allogeneic stem cell transplantation
Beyond the preview
Go deeper on 2013-000238-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000238-37.